Christophe Weber became president and CEO of Japan's Takeda Pharmaceutical on April 1, 2015, in the process becoming both the first non-Japanese and first corporate outsider to hold the position at the more than 230-year old company. He has since initiated a ground-up refocusing and restructuring that will alter the fundamental shape of the company while retaining its core identity.
Outgoing Eli Lilly CEO and president John Lechleiter looks back over his biggest strategic decisions while at the helm of the pharma major and pinpoints some of the key navigational markers for the next phase in Lilly's lifespan.
As he leaves after 23 years at the firm, outgoing CEO Eric-Paul Pâques talks about Grünenthal's growth and strategic priorities under his leadership while its new head, Gabriel Baertschi, brings his own brand of energy.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.